{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:26:30Z","timestamp":1783437990431,"version":"3.54.6"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T00:00:00Z","timestamp":1580947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T00:00:00Z","timestamp":1580947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Japanese Science Progress Society KAKENHI Grants","award":["17K11156"],"award-info":[{"award-number":["17K11156"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Increased expression of programmed cell death 1 ligand 1 (PD-L1) by tumor cells is thought to be a mechanism through which solid cancers promote immune tolerance. However, the association between PD-L1 expression and the prognosis of upper urinary tract urothelial carcinoma (UTUC) remains unknown.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We examined immunohistochemical PD-L1 expression and the tumor-infiltrating lymphocyte density (TILD) in 79 patients with UTUC who underwent nephroureterectomy. We classified the tumors into four types based on the combination of PD-L1 expression and TILD, and studied the clinicopathological characteristics of these four tumor types.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Elevated expression of PD-L1 by tumor cells and a higher TILD were associated with a worse histological grade, higher pT stage, and higher peripheral blood neutrophil-to-lymphocyte ratio. Elevated expression of PD-L1 by tumor cells, a higher TILD, and type I, III, or IV tumors with elevated expression of either PD-L1 or TILD showed a positive correlation with poorer differentiation and local invasion. These three variables were associated with shorter progression-free survival and overall survival in univariate analysis, but only the latter was an independent determinant according to multivariate analysis. The patients who had type II tumors with lower PD-L1 expression and a lower TILD showed more favorable survival than the other three groups.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>These findings suggest that PD-L1 expression and TILs in the tumor microenvironment influence the progression of UTUC. Accordingly, it is important to understand the immunologic characteristics of the tumor microenvironment to develop more effective treatment strategies for this cancer.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00262-020-02499-7","type":"journal-article","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T17:03:42Z","timestamp":1581008622000},"page":"689-702","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density"],"prefix":"10.1007","volume":"69","author":[{"given":"Akinori","family":"Nukui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7086-6964","authenticated-orcid":false,"given":"Takao","family":"Kamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Kijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Narimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunehito","family":"Kambara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Betsunoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitatsu","family":"Fukabori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-Ichiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,6]]},"reference":[{"key":"2499_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.eururo.2017.07.036","volume":"73","author":"M Roupr\u00eat","year":"2018","unstructured":"Roupr\u00eat M, Babjuk M, Comp\u00earat E, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Gontero P, Van Rhijn BWG, Mostafid AH, Palou J, Shariat SF (2018) European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol 73:111\u2013122. https:\/\/doi.org\/10.1016\/j.eururo.2017.07.036","journal-title":"Eur Urol"},{"key":"2499_CR2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/s0090-4295(98)00295-7","volume":"52","author":"MC Hall","year":"1998","unstructured":"Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG (1998) Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 52:594\u2013601. https:\/\/doi.org\/10.1016\/s0090-4295(98)00295-7","journal-title":"Urology"},{"key":"2499_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-164","author":"T Kamai","year":"2010","unstructured":"Kamai T, Shirataki H, Nakanishi K, Furuya N, Kambara T, Abe H, Oyama T, Yoshida K (2010) Increased Rac1 activity and Pak1 overexpression are associated with lymphovascular invasion and lymph node metastasis of upper urinary tract cancer. BMC Cancer. https:\/\/doi.org\/10.1186\/1471-2407-10-164","journal-title":"BMC Cancer"},{"key":"2499_CR4","doi-asserted-by":"publisher","first-page":"E28","DOI":"10.1111\/bju.12133","volume":"112","author":"N Tanaka","year":"2013","unstructured":"Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Kobayashi H, Miyazaki Y, Ide H, Obata J, Hoshino K, Shirotake S, Hayakawa N, Kosaka T, Miyajima A, Momma T, Nakagawa K, Hasegawa S, Nakajima Y, Oya M (2013) Patient characteristics and outcomes in metastatic upper tract urothelial carcinoma after radical nephroureterectomy: the experience of Japanese multi-institutions. BJU Int 112:E28\u2013E34. https:\/\/doi.org\/10.1111\/bju.12133","journal-title":"BJU Int"},{"key":"2499_CR5","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1002\/cncr.28146","volume":"119","author":"MD Galsky","year":"2013","unstructured":"Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Godbold J, Oh WK, Bamias A (2013) Nomogram for predicting survival in patients with unresectable and\/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer 119:3012\u20133019. https:\/\/doi.org\/10.1002\/cncr.28146","journal-title":"Cancer"},{"key":"2499_CR6","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.eururo.2011.03.023","volume":"59","author":"A Stenzl","year":"2011","unstructured":"Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA, European Association of Urology (EAU) (2011) Treatment of muscle-invasive and metastatic bladder cancer. Update of the EAU guidelines. Eur Urol 59:1009\u20131018. https:\/\/doi.org\/10.1016\/j.eururo.2011.03.023","journal-title":"Eur Urol"},{"key":"2499_CR7","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","volume":"71","author":"JA Witjes","year":"2017","unstructured":"Witjes JA, Lebret T, Comp\u00earat E, Cowan NC, De Santis M, Bruins HM, Hernandez V, Espinos EL, Dunn J, Rouanne M, Neuzillet Y, Veskim\u00e4e E, van der Heijden AG, Gakis G, Ribal MU (2017) Updated 2016 EAU guidelines on muscle-invasive and Metastatic Bladder Cancer. Eur Urol 71:462\u2013475. https:\/\/doi.org\/10.1016\/j.eururo.2016.06.020","journal-title":"Eur Urol"},{"key":"2499_CR8","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","volume":"17","author":"DF Bajorin","year":"1999","unstructured":"Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, Herr H, Higgins G, Boyle MG (1999) Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173\u20133181. https:\/\/doi.org\/10.1200\/JCO.1999.17.10.3173","journal-title":"J Clin Oncol"},{"key":"2499_CR9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.eururo.2010.06.029","volume":"58","author":"MG Kaag","year":"2010","unstructured":"Kaag MG, O'Malley RL, O'Malley P, Godoy G, Chen M, Smaldone MC, Hrebinko RL, Raman JD, Bochner B, Dalbagni G, Stifelman MD, Taneja SS, Huang WC (2010) Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 58:581\u2013587. https:\/\/doi.org\/10.1016\/j.eururo.2010.06.029","journal-title":"Eur Urol"},{"key":"2499_CR10","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1002\/cncr.25043","volume":"116","author":"BR Lane","year":"2010","unstructured":"Lane BR, Smith AK, Larson BT, Gong MC, Campbell SC, Raghavan D, Dreicer R, Hansel DE, Stephenson AJ (2010) Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer 116:2967\u20132973. https:\/\/doi.org\/10.1002\/cncr.25043","journal-title":"Cancer"},{"key":"2499_CR11","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"key":"2499_CR12","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science 331:1565\u20131570. https:\/\/doi.org\/10.1126\/science.1203486","journal-title":"Science"},{"key":"2499_CR13","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"key":"2499_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27:450\u2013461. https:\/\/doi.org\/10.1016\/j.ccell.2015.03.001","journal-title":"Cancer Cell"},{"key":"2499_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nri2326","volume":"8","author":"W Zou","year":"2008","unstructured":"Zou W, Chen L (2008) Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8:467\u2013477. https:\/\/doi.org\/10.1038\/nri2326","journal-title":"Nat Rev Immunol"},{"key":"2499_CR16","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O\u2019Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Drecier R (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicenter, phase 2 trial. Lancet 387:1909\u20131920. https:\/\/doi.org\/10.1016\/S0140-6736(16)00561-4","journal-title":"Lancet"},{"key":"2499_CR17","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF, KEYNOTE-045 Investigators (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015\u20131026. https:\/\/doi.org\/10.1056\/NEJMoa1613683","journal-title":"N Engl J Med"},{"key":"2499_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JA, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD (2017) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18:312\u2013322. https:\/\/doi.org\/10.1016\/S1470-2045(17)30065-7","journal-title":"Lancet Oncol"},{"key":"2499_CR19","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","volume":"75","author":"MW Teng","year":"2015","unstructured":"Teng MW, Ngiow SF, Ribas A, Smyth MJ (2015) Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 75:2139\u20132145. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0255","journal-title":"Cancer Res"},{"key":"2499_CR20","doi-asserted-by":"publisher","first-page":"e1134412","DOI":"10.1080\/2162402X.2015.1134412","volume":"5","author":"AS Baras","year":"2016","unstructured":"Baras AS, Drake C, Liu JJ, Gandhi N, Kates M, Hoque MO, Meeker A, Hahn N, Taube JM, Schoenberg MP, Netto G, Bivalacqua TJ (2016) The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. OncoImmunology 5:e1134412. https:\/\/doi.org\/10.1080\/2162402X.2015.1134412","journal-title":"OncoImmunology"},{"key":"2499_CR21","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.juro.2015.02.2941","volume":"194","author":"B Wang","year":"2015","unstructured":"Wang B, Wu S, Zeng H, Liu Z, Dong W, He W, Chen X, Dong X, Zheng L, Lin T, Huang J (2015) CD103+ Tumor infiltrating lymphocytes predict a favorable prognosis in urothelial cell carcinoma of the bladder. J Urol 194:556\u2013562. https:\/\/doi.org\/10.1016\/j.juro.2015.02.2941","journal-title":"J Urol"},{"key":"2499_CR22","doi-asserted-by":"publisher","first-page":"7485","DOI":"10.1038\/s41598-018-25944-1","volume":"8","author":"HS Huang","year":"2018","unstructured":"Huang HS, Su H, Li PH, Chiang PH, Huang CH, Chen CH, Hsieh MC (2018) Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy. Sci Rep 8:7485. https:\/\/doi.org\/10.1038\/s41598-018-25944-1","journal-title":"Sci Rep"},{"key":"2499_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/cas.13887","volume":"110","author":"B Wang","year":"2019","unstructured":"Wang B, Pan W, Yang M, Yang W, He W, Chen X, Bi J, Jiang N, Huang J, Lin T (2019) Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder. Cancer Sci 110:489\u2013498. https:\/\/doi.org\/10.1111\/cas.13887","journal-title":"Cancer Sci"},{"key":"2499_CR24","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wieneert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S, International TILs Working Group 2014 (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26:259\u2013271. https:\/\/doi.org\/10.1093\/annonc\/mdu450","journal-title":"Ann Oncol"},{"key":"2499_CR25","doi-asserted-by":"publisher","first-page":"44823","DOI":"10.1038\/srep44823","volume":"7","author":"D Jiang","year":"2017","unstructured":"Jiang D, Liu Y, Wang H, Wang H, Song Q, Sujie A, Huang J, Xu Y, Zeng H, Tan L, Hou Y, Xu C (2017) Tumour infiltrating lymphocytes correlate with improved survival in patients with esophageal squamous cell carcinoma. Sci Rep 7:44823. https:\/\/doi.org\/10.1038\/srep44823","journal-title":"Sci Rep"},{"key":"2499_CR26","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.euf.2016.11.011","volume":"3","author":"SL Skala","year":"2017","unstructured":"Skala SL, Liu TY, Udager AM, Weizer AZ, Montgomery JS, Palapattu GS, Siddiqui J, Cao X, Fields K, Abugharib AE, Soliman M, Hafez KS, Miller D, Lee CT, Alva A, Chinnaiyan AM, Morgan TM, Spratt DE, Jiang H, Mehra R (2017) Programmed death-ligand 1 expression in upper tract urothelial carcinoma. Eur Urol Focus 3:502\u2013509. https:\/\/doi.org\/10.1016\/j.euf.2016.11.011","journal-title":"Eur Urol Focus"},{"key":"2499_CR27","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B, Vera-Badillo FE, Aneja P, Oca\u00f1a A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106:dju124. https:\/\/doi.org\/10.1093\/jnci\/dju124","journal-title":"J Natl Cancer Inst"},{"key":"2499_CR28","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use so ware \u2018EZR\u2019 for medical statistics\u201d. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"2499_CR29","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00262-006-0266-z","volume":"56","author":"J Nakanishi","year":"2007","unstructured":"Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S (2007) Overexpression of B7\u2013H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 56:1173\u20131182. https:\/\/doi.org\/10.1007\/s00262-006-0266-z","journal-title":"Cancer Immunol Immunother"},{"key":"2499_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejso.2013.08.023","volume":"40","author":"E Xylinas","year":"2014","unstructured":"Xylinas E, Robinson BD, Kluth LA, Volkmer BG, Hautmann R, K\u00fcfer R, Zerbib M, Kwon E, Thompson RH, Boorjian SA, Shariat SF (2014) Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol 40:121\u2013127. https:\/\/doi.org\/10.1016\/j.ejso.2013.08.023","journal-title":"Eur J Surg Oncol"},{"key":"2499_CR31","doi-asserted-by":"publisher","first-page":"4800","DOI":"10.1158\/1078-0432.CCR-08-0731","volume":"14","author":"SA Boorjian","year":"2008","unstructured":"Boorjian SA, Sheinin Y, Crispen PL, Farmer SA, Lohse CM, Kuntz SM, Leibovich BC, Kwon ED, Frank I (2008) T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res 14:4800\u20134808. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0731","journal-title":"Clin Cancer Res"},{"key":"2499_CR32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00262-017-2093-9","volume":"67","author":"J Breyer","year":"2018","unstructured":"Breyer J, Wirtz RM, Otto W, Erben P, Worst TS, Stoehr R, Eckstein M, Denzinger S, Burger M, Hartmann A (2018) High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. Cancer Immunol Immunother 67:403\u2013412. https:\/\/doi.org\/10.1007\/s00262-017-2093-9","journal-title":"Cancer Immunol Immunother"},{"key":"2499_CR33","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2102","unstructured":"Fridman WH, Pag\u00e8s F, Saut\u00e8s-Fridman C, Galon J (2102) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12:298\u2013306. https:\/\/doi.org\/10.1038\/nrc3245","journal-title":"Nat Rev Cancer"},{"key":"2499_CR34","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1158\/1078-0432.CCR-14-2023","volume":"21","author":"H Kakavand","year":"2015","unstructured":"Kakavand H, Wilmott JS, Menzies AM, Vilain R, Haydu LE, Yearley JH, Thompson JF, Kefford RF, Hersey P, Long GV, Scolyer RA (2015) PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor-treated melanoma patients. Clin Cancer Res 21:3140\u20133148. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2023","journal-title":"Clin Cancer Res"},{"key":"2499_CR35","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1136\/gutjnl-2015-310839","volume":"66","author":"ED Thompson","year":"2017","unstructured":"Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, Anders RA, Kelly RJ (2017) Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut 66:794\u2013801. https:\/\/doi.org\/10.1136\/gutjnl-2015-310839","journal-title":"Gut"},{"key":"2499_CR36","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Han X (2015) Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 125:3384\u20133391. https:\/\/doi.org\/10.1172\/JCI80011","journal-title":"J Clin Invest"},{"key":"2499_CR37","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20:5064\u20135074. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3271","journal-title":"Clin Cancer Res"},{"key":"2499_CR38","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1158\/1078-0432.CCR-13-2797","volume":"20","author":"M Atefi","year":"2014","unstructured":"Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, Comin-Anduix B, Ribas A (2014) Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res 20:3446\u20133457. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2797","journal-title":"Clin Cancer Res"},{"key":"2499_CR39","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2018.07.036","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa CB, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ, TCGA Research Network, Weinstein JN, Kwiatkowski DJ, Lerner SP (2017) Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171:540\u2013556. https:\/\/doi.org\/10.1016\/j.cell.2018.07.036","journal-title":"Cell"},{"key":"2499_CR40","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ccell.2017.08.005","volume":"32","author":"CD Hurst","year":"2017","unstructured":"Hurst CD, Alder O, Platt FM, Droop A, Stead LF, Burns JE, Burghel GJ, Jain S, Klimczak LJ, Lindsay H, Roulson JA, Taylor CF, Thygesen H, Cameron AJ, Ridley AJ, Mott HR, Gordenin DA, Knowles MA (2017) Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency. Cancer Cell 32:701\u2013715. https:\/\/doi.org\/10.1016\/j.ccell.2017.08.005","journal-title":"Cancer Cell"},{"key":"2499_CR41","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/00005392-200102000-00092","volume":"165","author":"T Takahashi","year":"2001","unstructured":"Takahashi T, Kakehi Y, Mitsumori K, Akao T, Terachi T, Ogawa O, Habuchi T (2001) Distinct microsatellite alterations in upper urinary tract tumors and subsequent bladder tumors. J Urol 165:672\u2013677. https:\/\/doi.org\/10.1097\/00005392-200102000-00092","journal-title":"J Urol"},{"key":"2499_CR42","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16:275\u2013287. https:\/\/doi.org\/10.1038\/nrc.2016.36","journal-title":"Nat Rev Cancer"},{"key":"2499_CR43","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1172\/JCI96113","volume":"128","author":"H Lin","year":"2018","unstructured":"Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W (2018) Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade\u2013mediated tumor regression. J Clin Invest 128:805\u2013815. https:\/\/doi.org\/10.1172\/JCI96113","journal-title":"J Clin Invest"},{"key":"2499_CR44","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"BZ Qian","year":"2010","unstructured":"Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141:39\u201351. https:\/\/doi.org\/10.1016\/j.cell.2010.03.014","journal-title":"Cell"},{"key":"2499_CR45","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","volume":"133","author":"S Sakaguchi","year":"2008","unstructured":"Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 133:775\u2013787. https:\/\/doi.org\/10.1016\/j.cell.2008.05.009","journal-title":"Cell"},{"key":"2499_CR46","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nature Rev Immunol 9:162\u2013174. https:\/\/doi.org\/10.1038\/nri2506","journal-title":"Nature Rev Immunol"},{"key":"2499_CR47","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.clgc.2016.12.027","volume":"15","author":"M Marchioni","year":"2017","unstructured":"Marchioni M, Cindolo L, Autorino R, Primiceri G, Arcaniolo D, De Sio M, Schips L (2017) High neutrophil-to-lymphocyte ratio as prognostic factor in patients affected by upper tract urothelial cancer: a systematic review and meta-analysis. Clin Genitourin Cancer 15:343\u2013349.e1. https:\/\/doi.org\/10.1016\/j.clgc.2016.12.027","journal-title":"Clin Genitourin Cancer"},{"key":"2499_CR48","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00345-018-2235-5","volume":"36","author":"MD Vartolomei","year":"2018","unstructured":"Vartolomei MD, Kimura S, Ferro M, Foerster B, Abufaraj M, Shariat SF (2018) Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients. World J Urol 36:1019\u20131029. https:\/\/doi.org\/10.1007\/s00345-018-2235-5","journal-title":"World J Urol"},{"key":"2499_CR49","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12943-017-0707-7","volume":"16","author":"A Ocana","year":"2017","unstructured":"Ocana A, Nieto-Jim\u00e9nez C, Pandiella A, Templeton AJ (2017) Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer 16:137. https:\/\/doi.org\/10.1186\/s12943-017-0707-7","journal-title":"Mol Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02499-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-020-02499-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02499-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T01:55:32Z","timestamp":1612490132000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-020-02499-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,6]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["2499"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02499-7","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,6]]},"assertion":[{"value":"19 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted according to the tenets of the Declaration of Helsinki and was approved by the institutional ethics review board of Dokkyo Medical University Hospital (Approval No. 27144).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and ethical standards"}},{"value":"Before surgery, written consent regarding the use of surgical samples fixed in buffered formalin and medical records, as well as data publication was requested, and protection of patient privacy in future studies was guaranteed through a signed consent form approved by our institutional Committee on Human Rights in Research. Consequently, each patient in this cohort signed the consent form approved by our institutional Committee on Human Rights in Research prior to nephroureterectomy. Furthermore, surviving patients provided written consent for analysis of PD-L1 and TILD of the surgical samples and laboratory data of peripheral blood, through a signed form approved by our institutional Committee on Human Rights in Research (Approval No. 27144). In cases of patient death, consent for publication was sought orally from next of kin of the participant. All samples were anonymized before analysis to protect patient privacy.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}